Ethical and Legal Issues in Long-Term Care: Food for Futuristic Thought
Author(s)Kane, Rosalie A.
Allied Health Personnel
Allowing to Die
Third Party Consent
Full recordShow full item record
AbstractThe nursing home is a community, albeit an artificial one, where strangers come together. Ethicists are now giving thought to the nature of that community and the obligations of people within it to each other.
Journal of Long-Term Care Administration. 1993 Fall; 21(3): 66-74.
Showing items related by title, author, creator and subject.
“What Is PER?” Patient Engagement in Research as a HitBélisle-Pipon, Jean-Christophe; Del Grande, Claudio; Rouleau, Geneviève (Programmes de bioéthique, École de santé publique de l'Université de MontréalÉrudit, 2018)Engaging patients in research conduct and agenda setting is increasingly considered as an ethical imperative, and a way to transcend views of patients as passive subjects by fostering their empowerment. However, patient engagement in research (PER) is still an emerging approach with debated definitional and operational frameworks. This song addresses the sometimes difficult encounter and elusive mutual understanding between researchers and patients. “What is PER?” is an impressionistic illustration of the challenges and issues that can be found in the universe of patient engagement in research.
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.Inglis, S; Stewart, S (2012-02-02)The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir.